New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:20 EDTSLXP, JAZZ, AUXL, NPSP, HSP, AKRX, UTHR, MDVN, CBST, ALKSLeerink names top 10 acquisition candidates in biopharma
Leerink believes partnership and acquisition activity will remain a key feature of news flow and excess returns for investors in the biopharma industry during 2014 and into 2015. The firm's top 10 acquisition candidates in the space are: Alkermes (ALKS), Akorn (AKRX), Akorn (AUXL), Cubist (CBST), Hospira (HSP), Jazz Pharmaceuticals (JAZZ), Medivation (MDVN), NPS Pharmaceuticals (NPSP), Salix (SLXP) and United Therapeutics (UTHR).
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 9, 2015
07:31 EDTJAZZJazz Pharmaceuticals initiated with a Buy at Mizuho
Subscribe for More Information
October 7, 2015
05:30 EDTALKSAlkermes price target raised to $79 from $77 at Barclays
Subscribe for More Information
October 6, 2015
11:33 EDTALKSAlkermes label for Aristada better than expected, says Morgan Stanley
Subscribe for More Information
08:02 EDTALKSAlkermes approval brings 'key' near-term growth driver, says Leerink
Subscribe for More Information
07:02 EDTALKSAlkermes approval an incremental positive, says JPMorgan
Subscribe for More Information
06:44 EDTALKSAlkermes approval removes 'important overhang,' says Credit Suisse
Subscribe for More Information
October 5, 2015
18:24 EDTALKSAlkermes announces FDA approval of ARISTADA
Alkermes announced that the U.S. FDA has approved ARISTADA extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch ARISTADA immediately.
September 30, 2015
10:00 EDTMDVNOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Analog Devices (ADI) upgraded to Buy from Neutral at Citi... Asbury Automotive (ABG) upgraded to Neutral from Underperform at BofA/Merrill... Brookfield (BAM) upgraded to Outperform from Market Perform at BMO Capital... CNOOC (CEO) upgraded to Buy from Hold at Jefferies... Canadian Pacific (CP) upgraded to Buy from Neutral at Goldman... Citizens Financial (CFG) upgraded to Buy from Neutral at UBS... Esperion (ESPR) upgraded to Neutral from Sell at Chardan... HSBC (HSBC) upgraded to Buy from Neutral at UBS... Hecla Mining (HL) upgraded to Outperformer from Sector Performer at CIBC... Johnson Controls (JCI) upgraded to Outperform from Market Perform at William Blair... Level 3 (LVLT) upgraded to Buy from Neutral at UBS... Madison Square Garden (MSG) upgraded on asset value, share buyback outlook at Stifel... Medivation (MDVN) upgraded to Market Perform from Underperform at Cowen... PHH Corp. (PHH) upgraded to Buy from Neutral at Compass Point... Post Holdings (POST) upgraded to Buy from Neutral at SunTrust... Ralph Lauren (RL) upgraded to Buy from Neutral at UBS... Regions Financial (RF) upgraded to Buy from Hold at Sandler O'Neill... Shire (SHPG) upgraded to Hold from Reduce at HSBC... Sinopec (SNP) upgraded to Buy from Hold at Jefferies... Verifone (PAY) upgraded to Buy from Hold at Argus.
08:32 EDTJAZZJazz Pharmaceuticals' NDA for defibrotide accepted by FDA
Subscribe for More Information
06:26 EDTMDVNMedivation upgraded to Market Perform from Underperform at Cowen
Subscribe for More Information
06:03 EDTUTHRUnited Therapeutics announces settlement of patent litigation with Sandoz
United Therapeutics announced that it has entered into a Settlement Agreement with Sandoz relating to ongoing litigation concerning certain patents relating to United Therapeutics' product, Remodulin Injection, and Sandoz's Abbreviated New Drug Application, or ANDA, seeking approval by the FDA to market a generic version of Remodulin. Under the Settlement Agreement, United Therapeutics granted to Sandoz a non-exclusive license to manufacture and commercialize the generic version of Remodulin described in its ANDA filing in the United States beginning on June 26, 2018, although Sandoz may be permitted to enter the market earlier under certain circumstances. The license included in the Settlement Agreement does not permit Sandoz the right to manufacture a generic version of any other United Therapeutics product, such as Tyvaso Inhalation Solution or Orenitram Extended-Release Tablets, nor does it grant any rights with respect to any technology associated with the Remodulin Implantable System being developed by the Company and Medtronic Inc., or the pre-filled semi-disposable pump system being developed by the Company and DEKA Research & Development Corp. The Settlement Agreement does not grant Sandoz any rights other than those required to launch Sandoz's generic version of Remodulin. In accordance with the Settlement Agreement, the parties will submit the Settlement Agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
September 29, 2015
16:14 EDTMDVNMedivation says Chief Medical Officer Seely to retire
Subscribe for More Information
10:00 EDTAKRXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:17 EDTAKRXAkorn initiated with a Neutral at Nomura
Subscribe for More Information
September 28, 2015
07:27 EDTHSPFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
07:13 EDTAKRXAkorn launches Myorisan 30 mg Capsules
Akorn announced that it has launched the recently-approved 30 mg strength of Myorisan. This launch further builds the Myorisan product portfolio that also includes 10 mg, 20 mg and 40 mg capsules.
September 27, 2015
15:04 EDTMDVNMedivation announces updated Phase 2 data on enzalutamide for breast cancer
Medivation announced updated data from a Phase 2 trial evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced triple-negative breast cancer. Results from an exploratory overall survival analysis of study data were presented at the 2015 European Cancer Congress. A novel gene expression profiling assay was developed using data derived from the Phase 2 trial in patients with advanced TNBC, with a goal of developing a diagnostic test that could select patients who may respond to enzalutamide treatment. 47% of the enrolled patients tested positive for the novel gene expression profiling assay. An exploratory analysis of updated overall survival data demonstrated that those TNBC patients on enzalutamide whose tumors tested positive for the gene expression profile have to date experienced a 10.5-month longer median survival duration compared to those patients on enzalutamide whose tumor tested negative for the gene expression profile. The exploratory analysis demonstrated that median overall survival to date for diagnostic positive advanced TNBC patients treated with enzalutamide was 18 months compared with 7.5 months for diagnostic negative patients treated with enzalutamide.
September 25, 2015
13:51 EDTJAZZBMO's pharma predictions for rest of year include take on Mylan, Perrigo
BMO Capital analyst David Maris rolled out his rest of year predictions for the Specialty Pharmaceuticals space. Among them is his belief that Mylan (MYL) will be unsuccessful in acquiring Perrigo (PRGO). Perrigo will either be acquired by another company or make an acquisition itself, Maris tells investors in a research note. His other predictions include Jazz Pharmaceuticals (JAZZ) proving to be a good buying opportunity amidst the current negative sentiment and ZS Pharma (ZSPH) offering upside following the recent pullback given the potential for a near-term buyout and prospects for its "best in class drug for hyperkalemia" winning approval in 2016.
08:00 EDTAKRXAkorn price target lowered to $41 from $50 at Leerink
Subscribe for More Information
07:22 EDTUTHREuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use